Adage Capital Partners Gp, L.L.C. Ocuphire Pharma, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $59.7 Billion
- Q3 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Ocuphire Pharma, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 954,996 shares of OCUP stock, worth $935,896. This represents 0.0% of its overall portfolio holdings.
Number of Shares
954,996Holding current value
$935,896% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding OCUP
# of Institutions
54Shares Held
19.2MCall Options Held
0Put Options Held
0-
Perceptive Advisors LLC New York, NY4.33MShares$4.24 Million0.01% of portfolio
-
Bios Capital Management, LP Fort Worth, TX3.68MShares$3.61 Million7.42% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT3.35MShares$3.28 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.34MShares$1.32 Million0.0% of portfolio
-
Mink Brook Asset Management LLC West Palm Beach, FL1.24MShares$1.21 Million1.38% of portfolio
About Ocuphire Pharma, Inc.
- Ticker OCUP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,579,800
- Market Cap $20.2M
- Description
- Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...